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Abstract
OBJECTIVE: To investigate the effects of Yindanxin-
naotong capsule (YDXNTC) and main components
compatibility and ratios on myocardium against
ischemia/reperfusion injury and the effect's under-
lying mechanism.
METHODS: Myocardial ischemia/reperfusion injury
(MIRI) was induced by ischemia for 30 min and re-
perfusion for 30 min. Electrocardiogram data and
coronary flow were recorded, and superoxide dis-
mutase (SOD), malondialdehyde (MDA), lactate de-
hydrogenase, creatine kinase-MB, cardiac troponin
T and I (cTnT, cTnI) and interleukin-1β, interleukin-8,
interleukin-18 (IL-1β, IL-8, IL-18) in myocardium
were measured. Hypoxia/reoxygenation and hydro-
gen peroxide (H2O2) injury were induced by hypox-
ia for 3 h/reoxygenation for 2 h, and 100 μM H2O2
for 1 h, respectively, in vitro rat myocardial cells
(H9c2). Cell viability, SOD, MDA, cTnT and inflamma-
tory factors (IL-1β, IL-8 and IL-18) were determined,
and Toll-like receptor 4 (TLR-4) expression was mea-
sured by western blotting.
RESULTS: In the isolated heart experiment, elevat-
ed heart function, coronary flow and SOD levels,
and decreased MDA levels and inflammatory fac-
tors were noted in the YDXNTC, main components
and main components compatibility groups. Ven-
tricular tachycardia/ventricular fibrillation occur-
rence decreased in the ginkgo biloba extract (GBE),
and GBE and salvia miltiorrhiza ethanol extract
compatibility (SM-E, GSEC) groups. Lactic dehydro-
genase levels decreased in the YDXNTC and aque-
ous extract of salvia miltiorrhiza (SM-H) groups. Cre-
atine kinase-MB decreased with GBE, SM-E, SM-H
and GSEC treatment, and cTnI and cTnT levels de-
creased with GSEC. In the in vitro cell study,
YDXNTC and main components ratios improved
cell viability and SOD levels, and suppressed MDA,
cTnT and inflammatory factors. TLR-4 expression
was down-regulated.
CONCLUSION: YDXNTC and main components
compatibility showed protective effects on MIRI in
this rat model and in vitro study. Regulating the
Toll-like receptor signaling pathway may affect the
mechanism.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Myocardial ischemia caused by coronary heart disease
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is a major cause of death globally. Currently, reperfu-
sion therapy is the most effective way of treating acute
myocardial infarction. However, myocardial ischemia/
reperfusion injury (MIRI) is an important factor affect-
ing reperfusion treatment.1 After cardiac muscle experi-
ences ischemia, the ischemic myocardium and sur-
rounding tissue will suffer more serious injury as restor-
ing the blood supply can lead to energy failure, free
radical generation, calcium overload, inflammation
and other damage.1,2 Therefore, preventing and reduc-
ing reperfusion damage has become the focus for atten-
uating myocardial infarction.
Yindanxinnaotong capsule (YDXNTC) is a prepara-
tion made from Chinese herbal medicines, and has
prominent curative effects on cardiovascular and cere-
brovascular diseases.3,4 In clinical treatment, it is used,
amongst others, for angina pectoris and arrhythmia.3
However, studies on the pharmacological foundation
and the mechanisms by which it works are poorly un-
derstood and rarely reported.
In this study, an isolated heart perfusion rat model was
used to imitate MIRI to investigate the protective ef-
fects of YDXNTC on MIRI. The protective effects of
YDXNTC and the main components proportioning
on rat myocardial cells (H9c2) were studied using an
in vitro model of hypoxia/reoxygenation and hydrogen
peroxide (H2O2) injury to investigate the possible un-
derlying mechanisms.
MATERIALS ANDMETHODS
Reagents and instruments
Ginkgo biloba extract (GBE), ethanol extract of salvia
miltiorrhiza (SM-E), aqueous extract of salvia miltior-
rhiza (SM-H) and a mixed combination of other com-
ponents in YDXNTC (MC) were provided by Gui-
zhou Bailing Pharmaceutical Industry Co., Ltd. (Gui-
zhou, China). Adult male Sprague-Dawley rats (270±
20) g were purchased from the Laboratory Animal Cen-
ter of the Chinese People's Liberation Army Military
Academy of Medical Sciences (Beijing, China). Super-
oxide dismutase (SOD), malondialdehyde (MDA) and
lactate dehydrogenase (LDH) kits were from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China).
Creatine kinase-MB (CK-MB) and cardiac troponin I
(cTnI) kits were from BG Products Inc. (Wichita, KS,
USA). IL-1β was from Beijing North Biotechnology
Research Institute (Beijing, China). IL-8, IL-18 and
cardiac troponin T (cTnT) kits were from R&D Sys-
tems Inc. (Minneapolis, MN, USA). The Langendorff
isolated heart perfusion system was from Panlab (Barce-
lona, Adebayor Ansel, Spain). DFM-96 γ radioimmu-
noassay counter equipment was from Hefei
Zhongcheng Mechanical and Electrical Co. (Hefei,
China). The microplate reader was from Thermo Fish-
er Scientific Inc. (Waltham, MA, USA). The H9c2 cell
line was obtained from the Cell Resource Center of Pe-
king Union Medical College (Beijing, China). Fetal bo-
vine serum (FBS) was from Zhejiang Tianhang Bio-
technology Co., Ltd., (Deqing, Zhejiang, China). Be-
ta-actin and TLR-4 antibodies were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). HRP-labeled goat anti-mouse IgG was the prod-
uct of Beijing Golden Bridge Biotechnology Co., Ltd.
(Beijing, China). The electrophoresis device was from
Bio-Rad Laboratories Inc. (Hercules, CA, USA).
Protective effect of YDXNTC and main components
compatibility on MIRI
Group design: Sprague-Dawley rats were divided into
the following groups: (a) control; (b) model; (c)
YDXNTC (GBE, 0.025 mg/mL; SM-E, 0.013 mg/
mL; SM-H, 0.031 mg/mL; and MC, 0.05 mg/mL);
(d) GBE (GBE, 0.025 mg/mL); (e) SM-E (SM-E
0.04 mg/mL); (f) SM-H (SM-H, 0.4 mg/mL); (g) MC
(MC, 0.05 mg/mL); (h) GBE and SM-E compatibility
(GSEC) (GBE, 0.025 mg/mL and SM-E, 0.013 mg/
mL); (i) GBE and SM-H compatibility (GSHC)
(GBE, 0.025 mg/mL and SM-H, 0.031 mg/mL); and
(j) SM-E and SM-H compatibility (SEHC) (SM-E,
0.013 mg/mL and SM-H, 0.031 mg/mL). Six rats
were allocated to each group.
Ethical approval: all experimental procedures conformed
with the guidelines of the Animal Care Committee of
the China Academy of Chinese Medical Sciences.
Induction of MIRI: sprague-Dawley rats were anesthe-
tized with 20% urethane (1 g/kg), and the hearts were
rapidly excised and mounted on a Langendorff appara-
tus and perfused at a constant rate with Krebs –
Henseleit buffer (K-HB) containing (in mmol/L): Na-
Cl, 118; NaHCO3, 24; CaCl2-2H2O, 2.5; KCl, 4.7;
KH2PO4, 1.2; MgSO4-7H2O, 1.2; and glucose, 11 (pH
7.4).5,6 Fine platinum electrodes were placed on the
right atrium and apex of the left ventricle to record the
electrocardiogram. After stabilization, the control
group was perfused for 70 min; the model group was
perfused for 10 min and then subjected to 30 min isch-
emia followed by 30 min reperfusion; and the drug
groups were perfused for 10 min with K-HB contain-
ing drugs, followed by the same procedure as the mod-
el group.5,7
Electrocardiogram and coronary flow collection: the
electrocardiogram was recorded throughout the experi-
ment and cardiac arrest time, heart rebeat time, time to
regain normal rhythm, and the incidence and duration
of arrhythmias were determined.7 Coronary blood was
collected during stabilization at 5, 10, 15, 20, 25 and
30 min of the reperfusion period.
Determination of SOD, MDA, myocardial enzymes
and inflammatory factors: after reperfusion, hearts
were removed from the device and homogenized be-
fore being centrifuged for 10 min at 100 ×g. The super-
natant was stored at ﹣ 20℃ . SOD, MDA, LDH,
CK-MB, cTnI, cTnT, IL-1β, IL-8 and IL-18 were
measured.
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Protective effects and mechanisms of YDXNTC and
main components proportioning in H9c2 cells
Group design: cells were divided into groups to serve
as the control, model, YDXNTC and different ratios
of GBE, SM-E and MC (Table 1-3).8
Cell culture and treatment: cells were cultured in
high-glucose DMEM supplemented with 10% FBS
and a combination of penicillin-streptomycin in a hu-
midified 5% CO2 atmosphere at 37℃ . On reaching
90% confluence, cells were treated with YDXNTC
(21.88 μg/mL) and different concentrations of the pro-
portioning drugs (Table 3) for 24 h before modeling.
The hypoxia/reoxygenation injury model was estab-
lished through hypoxia 3 h/oxygen 2 h, and the H2O2 in-
jury model was established by the addition of 100 μM
H2O2 for 1 h.9,10
Cell viability assay: cells were dispersed with trypsin
and seeded at 8000-10 000 cells/well in a 96-well plate
overnight before treatment. Subsequently, 200 μL
MTT solution (5 mg/mL) was added and cells were in-
cubated at 37℃ for 4 h. The supernatant was removed,
and the insoluble formazan product was dissolved in
150 μL DMSO. Absorbance was measured with a mi-
croplate reader at a wavelength of 570 nm.
Determination of SOD, MDA, cTnT and inflammato-
ry factors: after model processing, the cell culture super-
natant was collected and used to detect SOD, MDA,
cTnT and inflammatory factors (IL-1β, IL-8 and
IL-18).
Western blotting analyses of TLR-4 expression: cells
were treated with different drugs for 24 h before being
subjected to model processing, after which, protein was
extracted. TLR-4 expression was detected by western
blotting.
Statistical analyses
All results are expressed as mean ± standard deviation
(SD). Differences between groups were compared us-
ing one way ANOVA with the independent samples
t-test. The incidence of ventricular tachycardia/ven-
tricular fibrillation (VT/VF) between groups was
compared using Fisher Chi-squared tests. Repeated
measures analysis of variance was used to compare
different time points between groups. A P-value of <
0.05 was considered statistically significant. Statistical
tests were performed using SPSS 17.0 (IBM, Ar-
monk, NY, USA).
RESULTS
Protective effects of YDXNTC and main components
compatibility on MIRI
Influence on VT/VF incidence: the results indicated
that GBE and GSEC reduced VT/VF occurrence com-
pared with the model group (P<0.05 and P<0.01, re-
spectively; Figure 1).
Impact on cardiac arrest time: cardiac arrest time in-
creased after the addition of YDXNTC, SM-E, SM-H,
MC, GSEC and SEHC compared with the model
group (P<0.05, Table 4).
Reduction in heart rebeat time: heart rebeat time de-
creased in all treatment groups compared with the
model group (P<0.05, Table 4).
Level
1
2
3
4
5
6
7
8
9
Factor
1
1
1
1
2
2
2
3
3
3
2
1
2
3
1
2
3
1
2
3
3
1
2
3
2
3
1
3
1
2
4
1
2
3
3
1
2
2
3
1
Table 1 Orthogonal array L9 (34)
Note: factor 1, 2, 3 and 4 are the experimental factors; level 1-9
are the test number.
Table 3 Main components proportioning design (μg/mL)
Group
A
B
C
D
E
F
G
H
I
GBE
0
0
0
50
50
50
100
100
100
SM-E
0
25
50
0
25
50
0
25
50
MC
0
100
200
100
200
0
200
0
100
Notes: according to the three factors, the first, second and third
columns of the orthogonal array L9 (34) were chosen to set the
proportioning groups. GBE: ginkgo biloba extract; SM-E: etha-
nol extract of salvia miltiorrhiza; MC: mixed compatibility of
other ingredients in YDXNTC. A-I are the groups of different
proportions of the experimental factors.
Level
1
2
3
Factor
GBE
0
50
100
SM-E
0
25
50
MC
0
100
200
Table 2 Orthogonal factor levels (μg/mL)
Notes: GBE: ginkgo biloba extract; SM-E: ethanol extract of sal-
via miltiorrhiza; MC: mixed compatibility of other ingredients
in YDXNTC. 1, 2 and 3 are the different levels of the experi-
mental factors.
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Effect on time to regain normal rhythm: the time to re-
gain normal rhythm decreased after pretreatment com-
pared with the model group (P<0.05, Table 5).
Influence on arrhythmia duration
The duration of arrhythmia decreased with the addi-
tion of the study drugs compared with the model
group (P<0.05, Table 5).
Improvement of coronary flow
The results showed that: (a) coronary flow of all
groups at stabilization did not change (P>0.05; Figure
2); (b) in the model group, coronary flow decreased
during reperfusion (P<0.05; Figure 2-4); (c) at 5 min
of reperfusion, coronary flow increased in YDXNTC,
GBE, SM-E, SM-H, MC and SEHC groups (P<0.05;
Figure 2); (d) at 10 min of reperfusion, coronary flow
increased in the drug groups except for the GBE,
GSEC and GSHC groups (P<0.05; Figure 2); (e) at 15
min of reperfusion, as well as YDXNTC and GBE, cor-
onary flow also increased in the other groups (P<0.05;
Figure 3); (f) at 20 min of reperfusion, coronary flow
markedly increased in the drug groups (P<0.05; Figure
3); (g) at 25 min of reperfusion, coronary flow was ele-
vated in all drug groups except the GSEC group (P<
0.05; Figure 4); (h) at 30 min of reperfusion, it was evi-
dent that drug pretreatment promoted coronary flow
relative to the model group for all groups except the
GSEC group (P<0.05; Figure 4).
Antioxidant function: SOD and MDA measurements
in the myocardial homogenate are summarized in Ta-
ble 6. Pretreatment raised the activity of SOD for all
drug groups except the SM-H, MC and GSHC groups
(P<0.05, Table 6). The addition of drugs reduced
MDA (P<0.05, Table 6).
Table 4 Effect on heart function (s, n=6, xˉ ±s)
Group
Control
Model
YDXNTC
GBE
SE-M
SE-H
MC
GSEC
GSHC
SEHC
Cardiac arrest time
-
525±26
1043±156a
660±116
932±91a
1354±171a
1066±67a
735±42a
519±70
775±93a
Heart rebeat time
-
158±31
32±7a
55±12a
50±16a
19±5a
30±6a
34±11a
34±6a
35±8a
Notes: cardiac arrest time: heart stopped time-point less isch-
emia time-point; Heart rebeat time: heart restoring time-point
less ischemia time-point. YDXNTC: all ingredients in the Yin-
danxinnaotong capsule (0.12 mg/mL, 20-day treatment course);
GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol ex-
tract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous ex-
tract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibili-
ty of other ingredients in YDXNTC (0.05 mg/mL); GSEC:
GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility;
GSHC: GBE (0.025 mg/mL) and SM-H (0.031 mg/mL) com-
patibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/
mL) compatibility. aP<0.05 vs model group.
Group
Control
Model
YDXNTC
GBE
SE-M
SE-H
MC
GSEC
GSHC
SEHC
Time to regain
normal rhythm
-
278±45
71±22a
238±51a
76±12 a
60±18 a
121±18a
81±16 a
63±18 a
108±24 a
Arrhythmia
duration time
-
1583±72
353±52a
421±92 a
696±35 a
602±140 a
909±56 a
191±57 a
631±160 a
336±110 a
Table 5 Effect on heart function (s, n=6, xˉ ±s)
Notes: time to regain normal rhythm: timepoint for heart to re-
store normal rhythm less ischemia time-point; Arrhythmia dura-
tion time: sum of all arrhythmia times. YDXNTC: Yindanxin-
naotong capsule (0.12 mg/mL, 20-day treatment course); GBE:
ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of
salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of sal-
via miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of oth-
er ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025
mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE
(0.025 mg/mL) and SM-H (0.031 mg/mL) compatibility; SE-
HC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compati-
bility. aP<0.05 vs model group.
Table 6 Effect on SOD and MDA (n=6, xˉ ±s)
Group
Control
Model
YDXNTC
GBE
SM-E
SM-H
MC
GSEC
GSHC
SEHC
SOD (U/mg prot)
63.1±4.7
31.8±3.7a
37.9±5.3b
38.0±7.6b
38.7±6.5b
34.6±2.9
19.7±3.5
40.5±3.2b
36.6±2.5
47.7±8.9b
MDA (nmol/mg prot)
10.2±1.8
30.9±5.1a
21.7±1.5b
14.7±3.5b
13.7±1.8b
23.0±2.0b
16.8±5.4b
9.9±1.4b
20.3±4.1b
23.9±6.6b
Notes: SOD: superoxide dismutase; MDA: malondialdehyde.
YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day
treatment course); GBE: ginkgo biloba extract (0.025 mg/mL);
SM-E: ethanol extract of salvia miltiorrhiza (0.04 mg/mL);
SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC:
mixed compatibility of other ingredients in YDXNTC (0.05 mg/
mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL)
compatibility; GSHC: GBE (0.025 mg/mL) and SM-H (0.031
mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and
SM-H (0.031 mg/mL) compatibility. aP<0.05, vs control group;
bP<0.05, vs model group.
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Effect on LDH, CK-MB, cTnI and cTnT: an obvious
reduction in LDH was evident after pretreatment with
YDXNTC and SM-H (P<0.05, Table 7). Additionally,
CK-MB also showed reduced levels after pretreatment
with GBE, SM-E, SM-H and GSEC (P<0.05, Table
7). Of note was the decrease in cTnI and cTnT detect-
ed in the GSEC group compared with the model
group (P<0.05, Table 7).
Influence on inflammatory factors: compared with the
model group, the addition of drugs evidently dimin-
ished IL-1β generation in all drug groups except for
the SM-H group. Pretreatment with drugs resulted in
decreased IL-8 levels apart from in the MC group. Ad-
ditionally, the IL-18 level in all drug groups except for
the MC and GSHC groups was obviously reduced (P<
0.05, Table 8).
Protective effects and mechanisms of YDXNTC and
main components proportioning in H9c2 cells
Cell viability assay: YDXNTC raised cell viability in
both hypoxia/reoxygenation and H2O2 injury cells (P<
0.05, Table 9). Ratios of GBE∶SM-E∶MC were 0∶1∶
4, 4∶1∶0, 2∶1∶2 and 1∶0∶2 increased the viability of
hypoxia/reoxygenation injury cells (P<0.05; Table 9).
The viability of H2O2 injury cells improved with differ-
ent proportions of GBE, SM-E and MC (P<0.05, Ta-
ble 9).
SOD and MDA determination: the result showed that
pretreatment with YDXNTC increased SOD and de-
creased MDA levels induced by hypoxia/reoxygenation
and H2O2 injury (P<0.05, Table 10). A marked in-
crease in SOD and decrease in MDA levels was seen in
hypoxia/reoxygenation injury cells when ratios of GBE
∶SM-E∶MC were 0∶1∶4, 1∶0∶2, 2∶1∶8, 4∶1∶0 and 2
∶1∶2 (P<0.05, Table 10). A clear increase in SOD and
reduced MDA was apparent with the different ratios of
GBE, SM-E and MC after injury with H2O2 (P<0.05,
Table 10).
Examination of cTnT: YDXNTC and different pro-
portions of GBE, SM-E and MC reduced cTnT in
hypoxia/reoxygenation injury cells (P<0.05, Table
11). With H2O2 injury cells, cTnT decreased with
the ratio of 2∶1∶2 (GBE∶SM-E∶MC) (P<0.05, Ta-
ble 11).
Determination of inflammatory factors
Inflammatory factors released in hypoxia/reoxygen-
ation injury cells: pretreatment with YDXNTC re-
duced the release of inflammatory factors (P<0.05, Ta-
ble 12). IL-1β release decreased in the GBE, SM-E and
MC groups at ratios of 0∶1∶4, 1∶0∶2, 2∶1∶8, 4∶1∶0
and 2∶1∶2 (P<0.05, Table 12). IL-8 release decreased
at ratios of 0∶1∶4, 1∶0∶2, 2∶1∶8, 1∶1∶0 and 2∶1∶2
(GBE∶SM-E∶MC) (P<0.05, Table 12). Additionally,
IL-18 was inhibited with the different proportioning
ratios of GBE, SM-E and MC (P<0.05, Table 12).
Inflammatory factor release of H2O2 injury cells:
YDXNTC decreased IL-1β release in injured cells (P<
0.05, Table 12). A decrease in IL-1β was evident in the
following ratios: 0∶1∶4, 1∶0∶2, 2∶1∶8, 4∶1∶0 and 2∶1
∶2 (GBE∶SM-E∶MC) (P<0.05, Table 13). Ratios of 0:
1∶4, 1∶0∶2, 2∶1∶8 and 4∶1∶0 (GBE∶SM-E∶MC) de-
creased IL-8 release (P<0.05, Table 13). IL-18 release
decreased at the following ratios: 0∶1∶4, 1∶0∶2 and 4∶
1∶0 (GBE∶SM-E∶MC) (P<0.05, Table 13).
Expression of TLR-4
YDXNTC decreased TLR-4 expression in hypoxia/re-
oxygenation and H2O2 injury cells (P<0.05; Figure 5).
The different proportions of main components also re-
duced TLR-4 expression induced by hypoxia/reoxygen-
ation injury (P<0.05; Figure 5). TLR-4 expression in-
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Figure 1 Effect on VT/VF incidence
VT: ventricular tachycardia; VF: ventricular fibrillation. YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment
course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous ex-
tract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025
mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025 mg/mL) and SM-H (0.031 mg/mL) compatibility; SEHC: SM-E
(0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. aP<0.01 vs control group; bP<0.01 vsmodel group; cP<0.05 vsmodel group.
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Figure 3 Coronary flow changes
YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: eth-
anol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility
of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025
mg/mL) and SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. aP<0.05, vs
control group; bP<0.05, vsmodel group.
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Figure 2 Coronary flow changes
YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: eth-
anol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility
of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025
mg/mL) and SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. aP<0.05 vs
control group; bP<0.05 vsmodel group.
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duced by H2O2 injury was down-regulated when ratios
of the main components were 0∶1∶4, 1∶0∶2, 1∶1∶0, 4
∶1∶0 and 2∶1∶2 (P<0.05, Figure 5).
DISCUSSION
Coronary heart disease is one of the common cardiovas-
cular diseases, and has a high incidence. Basic research
and clinical treatments for cardiovascular diseases are
in continuous development and great progress has
been made.1,11 Currently, treatment for coronary heart
diseases mainly lie in thrombolysis, intervention and
surgical bypass.12 Unfortunately, MIRI is a problem re-
gardless of the therapy used.12 MIRI can be aggravated
when the blood supply is recovering.13 Therefore, the
prevention and treatment of MIRI is a critical issue
that needs to be resolved.14
YDXNTC is refined from several kinds of natural Chi-
nese herbal medicines.15 It is used for angina pectoris,
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Figure 4 Coronary flow changes
YDXNTC: Yindanxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: eth-
anol extract of salvia miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility
of other ingredients in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025
mg/mL) and SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. aP<0.05, vs
control group; bP<0.05, vsmodel group.
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Group
Control
Model
YDXNTC
GBE
SE-M
SE-H
MC
GSEC
GSHC
SEHC
LDH (U/mg prot)
3134.66±491.30
5598.98±966.38a
4586.07±1055.22b
5300.63±414.39
4899.18±1122.33
4240.26±1208.27b
5302.90±317.72
5286.42±471.31
5263.89±178.14
6207.23±1118.2
CK-MB (ng/mL)
8.18±1.88
12.67±0.91a
12.69±1.28
9.29±2.33b
9.69±2.13b
8.65±0.91b
10.05±1.82
7.95±1.31b
10.10±1.26
11.60±1.87
cTnI (ng/mL)
0.38±0.03
0.57±0.05a
0.45±0.15
0.43±0.02
0.45±0.21
0.51±0.10
0.56±0.15
0.40±0.08b
0.64±0.06
0.68±0.12
cTnT (ng/L)
119.44±5.93
132.21±3.53a
123.02±8.64
123.11±9.75
123.47±8.78
125.17±11.01
127.37±7.27
120.06±3.78b
126.22±3.03
130.50±9.23
Table 7 Effect on myocardial enzyme markers (n=6, xˉ ±s)
Notes: LDH: lactic dehydrogenase; CK-MB: creatine kinase-MB; cTnI and cTnT: cardiac troponin I and T. YDXNTC: Yindanxinnao-
tong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of salvia miltior-
rhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of other ingredients in
YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025 mg/mL) and
SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. aP<0.05 vs control group;
bP<0.05 vs model group.
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hypertension and stroke caused by Qi stagnation,
blood stasis and phlegm obstruction.16 YDXNTC can
increase coronary blood flow and improve myocardial
ischemic and anoxic conditions.16 No research has yet
been reported on YDXNTC's pharmacological founda-
tion and underlying mechanisms.
In this study, Langendorff isolated hearts were used to
establish a rat model of MIRI and the protective effects
of YDXNTC and the dominant ingredients were inves-
tigated. The mechanisms for the protective effects of
YDXNTC were studied using an in vitro model of hy-
poxia/reoxygenation and H2O2 injury with rat myocar-
dial cells (H9c2).
The following results were observed: (a) YDXNTC im-
proved heart function, coronary flow and SOD, and
decrease MDA and the release of inflammatory factors,
and myocardial enzymes. These findings indicate that
YDXNTC has cardioprotective effects during MIRI;
(b) Main components compatibility exhibited an obvi-
ous effect on heart function and coronary flow. A re-
markable inhibition of MDA and increase in SOD
were observed. Additionally, the release of inflammato-
ry factors reduced, and cardiac troponin decreased, in
the GSEC group. This finding suggests that the main
components compatibility may have cardioprotective
properties; (c) Cell viability and the SOD level in hy-
poxia/reoxygenation and H2O2 injury models were ele-
vated by YDXNTC. YDXNTC also decreased MDA
levels and the release of inflammatory factors in the in-
jured cells. Cell cardiac troponin release decreased with
Table 8 Influence on myocardial inflammatory factors (ng/mL, n=6, xˉ ±s)
Group
Control
Model
YDXNTC
GBE
SE-M
SE-H
MC
GSEC
GSHC
SEHC
IL-1β
0.095±0.022
0.253±0.066a
0.132±0.033b
0.150±0.017b
0.185±0.012b
0.212±0.038
0.153±0.021b
0.130±0.035b
0.146±0.038b
0.126±0.025b
IL-8
240.392±9.472
274.269±7.566a
251.879±10.306b
256.010±13.569b
256.295±13.041b
247.308±21.304b
279.348±10.469
237.345±7.413b
257.009±7.137b
257.009±13.080b
IL-18
61.034±0.253
79.773±3.536a
68.253±3.625b
72.409±6.161b
69.128±0.875b
73.138±5.720b
74.377±5.992
62.741±3.025b
73.674±4.371
70.741±3.065b
Notes: MIRI: myocardial ischemia-reperfusion injury; IL-1β: interleukin 1β; IL-8: interleukin 8; IL-18: interleukin 18. YDXNTC: Yin-
danxinnaotong capsule (0.12 mg/mL, 20-day treatment course); GBE: ginkgo biloba extract (0.025 mg/mL); SM-E: ethanol extract of sal-
via miltiorrhiza (0.04 mg/mL); SM-H: aqueous extract of salvia miltiorrhiza (0.4 mg/mL); MC: mixed compatibility of other ingredients
in YDXNTC (0.05 mg/mL); GSEC: GBE (0.025 mg/mL) and SM-E (0.013 mg/mL) compatibility; GSHC: GBE (0.025 mg/mL) and
SM-H (0.031 mg/mL) compatibility; SEHC: SM-E (0.013 mg/mL) and SM-H (0.031 mg/mL) compatibility. aP<0.05, vs control group;
bP<0.05, vs model group.
Table 9 Influence on cell viability (%, n=6, xˉ ±s)
Group
Control
Model
YDXNTC
B
C
D
E
F
G
H
I
Hypoxia/reoxygenation injury
100.0±6.4
56.5±3.4a
65.1±2.1b
68.9±8.7b
81.6±4.7b
64.6±4.1b
48.4±6.2b
61.7±6.1
60.6±7.4
83.0±11.5b
75.9±2.7b
H2O2 injury
100.0±11.7
53.2±9.3a
78.6±3.9b
74.9±10.6b
72.9±5.6b
98.8±7.5b
102.9±6.3b
89.3±3.4b
93.8±3.3b
114.9±8.6b
105.1±11.6b
Notes: H2O2: hydrogen peroxide. YDXNTC: Yindanxinnaotong capsule (21.88 μg/mL). B-I are the proportioning groups of GBE∶SM-E∶
MC. B: 0∶1∶4; C: 0∶1∶4; D: 1∶0∶2; E: 2∶1∶8; F: 1∶1∶0; G: 1∶0∶2; H: 4∶1∶0; I: 2∶1∶2. aP<0.05, vs control group; bP<0.05, vs model
group.
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YDXNTC after cells were injured by hypoxia/reoxygen-
ation. These findings indicate that YDXNTC also had
a protective effect on hypoxic injuries; (d) In the hy-
poxia/reoxygenation and H2O2 injury models, there
was an increase in cell viability and SOD levels by pre-
treatment with different proportions of the main com-
ponents. A reduction in MDA levels, the release of in-
flammatory factors and cardiac troponin levels were ob-
served in the proportioning groups. These findings sug-
gest the cardioprotective effects of the main compo-
nents proportioning; (e) YDXNTC resulted in the
down- regulation of TLR-4 expression in hypoxia/reox-
ygenation and H2O2 injured cells. Main components
proportioning also reduced TLR-4 expression. These
findings suggest that the mechanism by which
YDXNTC protects myocardial cells from ischemic in-
jury may be related to regulating the Toll-like receptor
pathway.
In conclusion, this study supports findings of the pro-
tective efficacy of YDXNTC on rat models of myocar-
dial ischemia/reperfusion injury. The mechanism be-
hind the protective effects may be related to the actions
of antioxidants, anti-inflammatory damage, alleviating
calcium overload and Toll-like receptor regulation. Fur-
ther study is required to confirm these findings.
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Figure 5 TLR-4 expression
A: TLR-4 of hypoxia/reoxygenation injury; B: TLR-4 of H2O2 injury. TLR-4: toll-like receptor 4; 1: control group; 2: model group; 3: Yin-
danxinnaotong capsule (21.88 μg/mL). 4 to 11 are the proportioning groups of GBE∶SM-E∶MC. 4: 0∶1∶4; 5: 0∶1∶4; 6: 1∶0∶2; 7: 2∶1
∶8; 8: 1∶1∶0; 9: 1∶0∶2; 10: 4∶1∶0; 11: 2∶1∶2. aP<0.05, vs control group; bP<0.05, vsmodel group.
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